RedHill Biopharma Files 6-K on Opaganib Progress

TL;DR

**RedHill Biopharma just filed a 6-K, likely with news on their drug Opaganib, so keep an eye out for details!**

AI Summary

RedHill Biopharma Ltd. filed a Form 6-K on February 20, 2024, indicating it is a foreign private issuer. The filing incorporates by reference a press release titled "RedHill's Opaganib Pr..." which likely discusses developments related to their drug Opaganib. The company's business address is 21 Ha'arba'a Street, Tel Aviv, Israel, and its SEC file number is 001-35773.

Why It Matters

This filing signals potential news regarding RedHill Biopharma's drug Opaganib, which could impact the company's valuation and future prospects in the pharmaceutical market.

Risk Assessment

Risk Level: low — This 6-K filing is purely administrative, reporting a press release, and does not inherently carry significant risk.

Key Numbers

• 001-35773 — SEC File Number (identifies the company's registration with the SEC)
• 20240220 — Filing Date (date the 6-K was filed)

Key Players & Entities

• RedHill Biopharma Ltd. (company) — registrant
• Opaganib (company) — drug mentioned in press release
• February 2024 (date) — month of report
• 001-35773 (dollar_amount) — SEC file number
• 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (company) — principal executive offices

FAQ

Filing Documents

• zk2431016.htm (6-K) — 39KB
• image00001.jpg (GRAPHIC) — 11KB
• 0001178913-24-000651.txt ( ) — 56KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REDHILL BIOPHARMA LTD. (the "Registrant") Date: February 20, 2024 By: /s/ Dror Ben-Asher Name: Dror Ben-Asher Title: Chief Executive Officer Press Release RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis – New Publication The data, published in the International Journal of Molecular Sciences, demonstrate that opaganib significantly improved long-term survival in an in vivo model of lung damage following exposure to ionizing radiation -- Opaganib is the first selective sphingosine kinase-2 (SPHK2) inhibitor investigational drug targeting sphingolipid metabolism for the treatment of radiation-induced inflammation -- Opaganib, a novel oral, small molecule pill with a five-year shelf-life, is easy to administer and distribute, supporting potential central government stockpiling for use as radioprotection therapy in mass casualty radiological or nuclear incidents, if approved by the FDA -- Opaganib is being tested as a potential treatment for Acute Radiation Syndrome (ARS) following selection by the U.S government National Institutes of Health's (NIH) Radiation and Nuclear Countermeasures Program (RNCP) for its radiation medical countermeasures Product Development Program -- Opaganib is being developed for multiple additional indications, including COVID-19, acute respiratory distress syndrome (ARDS), filoviruses (including Ebola) and oncology TEL AVIV, ISRAEL & RALEIGH, N.C., February 20, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced a new publication of data from multiple experiments in the International Journal of Molecular Sciences 1 . The published data shows that opaganib 2 protects against radiation-induced lu

Forward Looking Statements

Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements, including, but not limited to, statements regarding the intended use of net proceeds from the offering, may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words and include statements regarding the risk that the Company will not comply with the listing requirements of the Nasdaq Capital Market ("Nasdaq") to remain listed for trading on Nasdaq, the addition of new revenue generating products, out-licensing of the Company's development pipeline assets, timing of opaganib's development for Acute Radiation Syndrome, non-dilutive development funding from RHB-107 and its inclusion in a key platform study. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, market and other conditions, the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that acceptance onto the RNCP Product Development Pipeline will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for opaganib for any indication, the risk that observations from preclinical studies are not indicative or predictive of results in clinical trials; the risk that the FDA pre-stu

View Full Filing

View this 6-K filing on SEC EDGAR